ABEO (Abeona Therapeutics) Net Margin %: -195.81% (As of Mar. 2026)

What is Abeona Therapeutics Net Margin %?

Abeona Therapeutics ABEO +0.99% 31 Net Margin % is -195.81% as of Mar. 2026. GuruFocus rates ABEO with a GF Score™ of 31/100. The stock has 7 warning signs investors should review. Among 946 Biotechnology companies, Abeona Therapeutics ranks better than 99.15% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Abeona Therapeutics's Net Income for the three months ended in Mar. 2026 was $-17.08 Mil. Abeona Therapeutics's Revenue for the three months ended in Mar. 2026 was $8.72 Mil. Therefore, Abeona Therapeutics's net margin for the quarter that ended in Mar. 2026 was -195.81%.

The historical rank and industry rank for Abeona Therapeutics's Net Margin % or its related term are showing as below:

ABEO' s Net Margin % Range Over the Past 10 Years
Min: -3263.92 Med: -2175.35 Max: 1223.08
Current: 454.86

ABEO's Net Margin % is ranked better than
99.15% of 946 companies
in the Biotechnology industry
Industry Median: -88.815 vs ABEO: 454.86

Abeona Therapeutics (NAS:ABEO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Abeona Therapeutics Net Margin % Related Terms

Abeona Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Abeona Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abeona Therapeutics Net Margin % Chart

Abeona Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Net Margin %

Get a 7-Day Free Trial

-2,831.20

-2,807.36

-1,548.23

0.00

1,223.08

Abeona Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Net Margin %	Get a 7-Day Free Trial															0.00	27,208.25	0.00	-377.49	-195.81

ABEO vs FATE, LCTX, BCYC: Net Margin % Comparison

For the Biotechnology subindustry, Abeona Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abeona Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's Net Margin % falls into.

Save Embed

31GF Score

Abeona Therapeutics Inc ABEO

Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Abeona Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Abeona Therapeutics's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin	=	Net Income (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	71.183	/	5.82
	=	1,223.08 %

Abeona Therapeutics's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin	=	Net Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-17.075	/	8.72
	=	-195.81 %

Frequently Asked Questions Learn more about Net Margin % →

What does a Net Margin % of -195.81% mean?

Abeona Therapeutics (ABEO) has a Net Margin % of -195.81% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Abeona Therapeutics and its competitors. According to the industry distribution chart, Abeona Therapeutics ranks #8 out of 946 companies in the Biotechnology industry, placing it in the top 0.8%.

Is Abeona Therapeutics' Net Margin % too high?

Abeona Therapeutics' current Net Margin % is -195.81%. Based on the distribution chart, Abeona Therapeutics ranks #8 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Abeona Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.

How does Abeona Therapeutics' Net Margin % compare to FATE and LCTX?

According to the Biotechnology industry distribution chart, Abeona Therapeutics ranks #8 out of 946 companies for Net Margin %. This places Abeona Therapeutics in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Net Margin % for a Biotechnology company?

A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Net Margin % mean?

A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Abeona Therapeutics and its competitors. Abeona Therapeutics's current Net Margin % is -195.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Abeona Therapeutics stock overvalued right now?

Abeona Therapeutics (ABEO) has a current Net Margin % of -195.81%. The current Net Margin % is -195.81%. Abeona Therapeutics' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Net Margin % calculated?

Net Margin % is calculated from a company's financial statements. For Abeona Therapeutics (ABEO), the current Net Margin % is -195.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Abeona Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies FATE LCTX BCYC RCKT IVVD DMAC NMRA RZLT TENX NAUT VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 0H7R:UK PCJ:Germany

Address 6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103

Website https://www.abeonatherapeutics.com

Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

31GF Score

Get the complete analysis for ABEO

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.61

Price

View ABEO Analysis

See Net Margin % data for all stocks →